U.S. markets open in 6 hours 6 minutes
  • S&P Futures

    3,837.50
    -5.00 (-0.13%)
     
  • Dow Futures

    30,757.00
    -85.00 (-0.28%)
     
  • Nasdaq Futures

    13,539.25
    +53.75 (+0.40%)
     
  • Russell 2000 Futures

    2,133.60
    -12.20 (-0.57%)
     
  • Crude Oil

    53.01
    +0.40 (+0.76%)
     
  • Gold

    1,849.30
    -1.60 (-0.09%)
     
  • Silver

    25.46
    -0.08 (-0.31%)
     
  • EUR/USD

    1.2154
    -0.0015 (-0.12%)
     
  • 10-Yr Bond

    1.0400
    0.0000 (0.00%)
     
  • Vix

    23.02
    -0.17 (-0.73%)
     
  • GBP/USD

    1.3738
    +0.0006 (+0.05%)
     
  • USD/JPY

    103.7060
    +0.0790 (+0.08%)
     
  • BTC-USD

    31,689.48
    +363.52 (+1.16%)
     
  • CMC Crypto 200

    636.45
    -3.47 (-0.54%)
     
  • FTSE 100

    6,625.18
    -28.83 (-0.43%)
     
  • Nikkei 225

    28,635.21
    +89.03 (+0.31%)
     

Allena Pharmaceuticals Inc (NASDAQ:ALNA): Are Analysts Bull Or Bear?

Felix Olson

The most recent earnings announcement Allena Pharmaceuticals Inc’s (NASDAQ:ALNA) released in December 2017 confirmed company earnings became less negative compared to the previous year’s level – great news for investors Investors may find it useful to understand how market analysts predict Allena Pharmaceuticals’s earnings growth outlook over the next few years and whether the future looks brighter. I will be using net income excluding extraordinary items in order to exclude one-off volatility which I am not interested in. Check out our latest analysis for Allena Pharmaceuticals

Market analysts’ consensus outlook for next year seems pessimistic, with earnings becoming even more negative, arriving at -US$30.43M in 2019. Furthermore, earnings are expected to fall off in the following year, falling to -US$34.63M in 2020 and -US$48.36M in 2021.

NasdaqGS:ALNA Future Profit Apr 20th 18
NasdaqGS:ALNA Future Profit Apr 20th 18

Although it is useful to understand the growth each year relative to today’s level, it may be more valuable estimating the rate at which the business is rising or falling on average every year. The benefit of this method is that it removes the impact of near term flucuations and accounts for the overarching direction of Allena Pharmaceuticals’s earnings trajectory over time, fluctuate up and down. To compute this rate, I put a line of best fit through the forecasted earnings by market analysts. The slope of this line is the rate of earnings growth, which in this case is -11.15%. This means, we can assume Allena Pharmaceuticals will chip away at a rate of -11.15% every year for the next few years.

Next Steps:

For Allena Pharmaceuticals, I’ve put together three fundamental aspects you should further examine:

  1. Financial Health: Does it have a healthy balance sheet? Take a look at our free balance sheet analysis with six simple checks on key factors like leverage and risk.

  2. Future Earnings: How does ALNA’s growth rate compare to its peers and the wider market? Dig deeper into the analyst consensus number for the upcoming years by interacting with our free analyst growth expectation chart.

  3. Other High-Growth Alternatives: Are there other high-growth stocks you could be holding instead of ALNA? Explore our interactive list of stocks with large growth potential to get an idea of what else is out there you may be missing!


To help readers see pass the short term volatility of the financial market, we aim to bring you a long-term focused research analysis purely driven by fundamental data. Note that our analysis does not factor in the latest price sensitive company announcements.

The author is an independent contributor and at the time of publication had no position in the stocks mentioned.